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Research article    
Unmodifiable variables related to thyroid 
cancer incidence  
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Cristina Orlov1, Silviu Pituru2, Dana L. Stanculeanu2, Razvan Hainarosie2, Anca Pantea 
Stoian6, Adrian Tulin2,3 
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 University of Medicine and Pharmacy, Bucharest, Romania 
3Department of General Surgery, 4Department of Endocrinology, 5Department of Plastic Surgery, Prof. Dr.   
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Abstract The incidence of thyroid cancer is significantly different between male and female 
patients. Thyroid cancer is also the only form of cancer where age can be considered a 
staging variable. Identifying biological prognostic factors such as age or sex is important 
as it helps select an optimal personalized therapy. The present analysis is an 
observational, prospective study that enrolled all patients with thyroid disease who were 
operated upon at a single center. The study aimed to determine the most frequent age at 
presentation, the predominance of one sex over the other, the incidence of malignant 
thyroid disease, and the relative risk for each sex to develop thyroid carcinoma. The 
incidence of thyroid carcinoma was higher for women than for men, with a higher 
relative risk in the female subgroup. Incidence was also highest in the 50-60-year-old 
group. Given that studies show better survival for women and for younger patients, even 
when presenting with advanced disease, compared with older, male patients, such 
prognostic indicators should be a factor in the treatment decision.        
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Highlights ✓ The incidence of thyroid carcinoma seems to be higher for women than for men,  
✓ Women and for younger patients present better survival, even when they present with 
advanced disease, as compared with older, male patients.    
✓ Such prognostic indicators should be considered important factors in the therapeutic 
decision        
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Introduction 
Significant variation in the incidence of thyroid 
cancer among women and men has long led to 
speculation about the possible biological theories 
underlying the development and progression of this 
disease. The annual percentage of thyroid malignancies 
for both women and men increased between 1980 and 
1997 by 2.4% per year, and by 6.6% per year between 
1997 and 2009 (1). This increase does not necessarily 
reflect a higher incidence, but only the possible 
expansion of screening techniques that provide easier 
access for diagnosis.  
Thyroid cancer is the most common malignant 
disease of the endocrine system and the 7th most 
common neoplasia in women, although in the case of 
men, it is not among the 15 most frequent cancers (2). 
Thyroid cancer is the only form of cancer where age can 
be considered a staging variable (3). This study 
attempted to identify whether a link exists between age 
and sex of the patient and the risk of developing a certain 
type of thyroid cancer, while taking into account these 
two unchangeable variables. Identifying prognostic 
factors such as age or sex is important as it helps in 
determining an optimal personalized therapy instead of 
deciding treatment strictly based on the underlying 
disease.  
Materials and methods  
This observational, prospective study enrolled all 
patients with thyroid disease who were operated upon 
between January 2015 to January 2018 in the Clinic of 
General Surgery of the Emergency Clinical Hospital 
“Prof. Dr. Agrippa Ionescu,” Bucharest, Romania, 
irrespective of the operative indication which included: 
symptomatic thyroid masses and goiter, refractory 
Graves disease or hyperthyroidism, or biopsy-proven 
thyroid cancer or solitary nodules with malignant 
characteristics on ultrasound. Exposure to prior 
radiation was an exclusion criterion. After completing 
the surgery, data regarding the patient’s age, gender, and 
pathology report were collected. SPSS Statistics version 
20 was used for data analysis. The ethics comittee 
approved data collection for this research. All patients 
signed an informed consent and agreed to the usage of 
the data. 
Results 
A total of 189 patients were included in the study. 
Of these, 171 (90.47%) were women and 18 (9.53%) 
were men. All patients underwent total thyroidectomy. 
Mean age of the entire group was 48,94 (minimum, 21; 
maximum 69,  SD =  12,7). Mean age of the male group 
was 48.61 (minimum, 33; maximum, 69; SD =11.63), 
whereas for women the mean age was 48,84 (minimum, 
21; maximum, 69). Of the women, 76% (n=130) had no 
cancerous lesion on the thyroidectomy pathology report, 
while 24% (n=41) tested positive for cancer. 
Clinicopathologic characteristics of these patients are 
presented in Table 1.   
 
Among men, 33.3% (n=6) had thyroid carcinoma 
and 66.7% (n=12) were free of neoplastic disease on 
pathology evaluation. The relative risk for malignancy 
among women was 1.140 (95% CI 0.56-4.49), OR 1.140 
(95% CI 0.81-1.59). Among men, the relative risk for 
malignancy was 0.409 (95% CI 0.4-0.86), OR 0.75 
(95% CI 0.5-1.1). The incidence of thyroid cancer in the 
two sexes was higher in women (Figure 1). Female to 
male ratio in the thyroid carcinoma subgroup was 
3.23:0.90.  The most frequent histologic subtype was 
papillary thyroid cancer (see Figure 1 for the carcinoma 
incidence by sex and age group).  
Variable Nr. 
Percentage 
% 
Sex m 7 14,58% 
f 41 85,41% 
Age  
(years) 
21-30 4 8,33% 
31-40 9 18,75% 
41-50 14 29,16% 
51-60 16 33,3% 
61-70 10 20,83% 
Histology papillary 45 93,75% 
follicular 3 6,25% 
medular 1 2% 
anaplastic 1 2% 
Multifocality  10 20,83% 
Capsular 
invasion 
 7 14,58% 
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Figure 1. Graphic representation of the carcinoma 
incidence for each gender 
 
Figure 2. Graphic representation of the carcinoma 
incidence for each age subgroup 
Patients were classified into 5 age groups in order 
to establish incidence rates. 7.9% (n=15) of the patients 
were 20-30 years old, 15.8% (n=30) were 30-40, 
25.38% (n=48) were 40-50, 31.21% (n=59) were 50-60, 
and 19.57% (n=37) were 60-70. Of these, in the most 
representative group (50-60) 74.6% (n=44) were 
positive for cancer (Figure 2). Patients were thus divided 
into two subgroups: patients under 40 years, 51.32% 
(n=97), and patients over 40, 48.68% (n= 92). Relative 
risk for thyroid malignancy was 0.6 (95% CI 0.32-1.25) 
in the under 40 subgroup, OR= 0.89 (0.76-1.05) . 
 
Discussion 
Identification of prognostic factors such as age and 
sex allow the patient to be classified epidemiologically 
and offers an optimal path of treatment. Even if the 
prognosis of well-differentiated thyroid carcinomas as 
localized disease is excellent, in cases of regional 
disease or remote metastasis, survival may be influenced 
by age (4). In this sample, females had higher 
percentages among those who were both diagnosed and 
operated for various thyroid pathologies. The most 
frequent operative indication was polinodular goiter. 
Among objective criteria, hormonal activity and their 
oscillation both during the menstrual cycle and during 
pregnancy seem to positively influence this increased 
incidence. The peak incidence of thyroid cancer in the 
female subgroup occurred in the 50-60-year age group, 
this being the age most women become menopausal. 
Similar results have been reported elsewhere (5). 
However, the impact of hormonal oscillations cannot be 
clearly quantified; data collected by Negri et al. did not 
reveal a statistically significant link between 
reproductive factors and the incidence of thyroid cancer 
(6). Among potential risk factors, late menstruation, late 
delivery of the first child, surgically or medication-
induced menopause, and abortion were listed. Truong et 
al. also identified an association between menopausal 
status and an increased incidence of thyroid cancer (7).  
The peak incidence for thyroid carcinoma in men is 
reached at 60-69 years. The incidence rate between the 
two sexes is reported in the literature to be almost 
identical among 80-year-olds. (4). In our study, it was 
difficult to establish age subgroups having the most 
similar incidence, given the fact that women greatly 
outnumbered men. The related sex difference in 
incidence, aggressiveness, and prognosis of neoplasms 
has been observed for a variety of cancers. In sex-
specific organs such as the uterus, prostate, ovary, and 
breast, this difference can easily be explained. However, 
some localizations found in both sexes, such as the 
thyroid, lung and liver also indicate clear sex differences 
in incidence and/or survival (2, 4, 8, 9). 
Women have malignancy onset at a lower age, but 
men often have a more aggressive or advanced form at 
the time of diagnosis. The Age, Metastasis, Size and 
Size (AMES) criteria, which classify patients with low 
or high risk based on age, metastasis, tumour invasion, 
and tumour size, takes into account sex differences in 
patient risk stratification. The age limit at which patients 
without distant metastases are considered at high risk 
and, therefore, the less favorable prognosis, is 10 years 
lower for men (41 years) compared to women (51 years) 
(10). Other systems that use sex as a variable in staging 
include the European Organization for the Study and 
Treatment of Cancer and the gender, age and grade 
classification (11). 
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The role of sex hormones, which is well 
documented in both breast and prostate cancer, warrants 
mentioning. The function of these hormones is mediated 
through cellular nuclear receptors that can activate or 
inactivate certain genes having the potential to influence 
the biology of the tumour (12). Nuclear receptors of 
estrogen (alpha and beta estrogens) are well expressed 
in thyroid cancer, especially in the papillary forms 
which, as we observed in our study, was frequently 
encountered; with a total of 45 of 48 cases, 43 were 
identified in the female subgroup (13).  
The prospective cohort study conducted by 
Iribarren et al. in 2001 on 204,964 people reported a 
relative risk for women to develop thyroid cancer of 1.56 
(14). Our study reported a lower relative risk, probably 
because our sample size was lower, and the age of our 
sample was both lower and did not include as many 50-
60-year-old women. Although more common in women, 
thyroid cancer in men has a more aggressive progression 
with a worse prognosis. Kruijff and colleagues have 
shown that the risk of recurrence is 2.44 times higher in 
men than in women at a median follow-up period of 31 
months (14, 15). 
As we have seen in our study, only 7 cases of 
thyroid cancer were seen in men, and two of these had 
an aggressive form: 1 case was anaplastic, 1 medullary 
case. Also, regarding staging, 4 of them were classified 
as advanced T3-T4 stages according to TNM.  
Liu, in a recent article evaluating the prognostic role 
of the male sex in thyroid cancer, has confirmed its 
association with an increased risk of death, but this 
association disappears when adjustments are made for 
age, multifocality, and treatment received (16). 
Although current studies suggest that complete surgical 
resection and adjuvant radiotherapy is the standard of 
care, such factors as age, sex, and clinical-pathological 
parameters such as superior tumour grade (III / IV) and 
stage of cancer should be considered when assessing the 
risk of mortality in differentiated thyroid tumours (17). 
Unfortunately, the details of surgical therapies and 
radiotherapy were incomplete in the use of the survival 
analysis database. Further research is needed to discover 
the source of sex differences, implying interrelated 
(genomic and epidemiological) investigative studies, 
rather than the competitiveness between the various 
research groups (18). However, given the aggressive 
features and poor prognosis associated with aging, up-
front adequate surgery should not be excluded from 
other therapeutic options in the elderly. It is known that 
increasing age negatively affects the prognosis of 
thyroid cancer, and thus previous studies have used 
various ages as cutoff points for prognostic value (19).  
Papillary thyroid carcinoma is the most frequently 
encountered type of carcinoma reported in patients 
positive for malignancy and is known for its good 
prognosis regarding survival. However, some 
histological subtypes, like the tall cell variant for 
example, do not warrant such an optimistic prognosis 
(20). Other aggressive histological subtypes like 
medullary carcinoma are very often part of a genetically 
inherited syndrome, such as MEN (multiple endocrine 
neoplasias), and do not follow the incidence pattern of 
more frequent ones (21). 
Gilliland et al. and later, Hundahl et al. both 
demonstrated that the patient's age at presentation is an 
independent factor associated with survival, so young 
patients diagnosed with an advanced stage disease have 
a better survival than the elderly with an early stage 
disease. The explanation for this pattern is still unknown 
(22-24). In our study, mean age of the patients was 
nearly identical in the two subgroups.  
Some retrospective trials have suggested that young 
adults present with advanced stage more often and have 
more frequent recurrences than patients over 65.5 years 
old. Even so, paradoxically, overall survival is superior 
in the young patient subgroup (25, 26).   
 
Conclusions 
Women present more often with thyroid disease for 
which surgery is mandatory. Age at presentation was 
similar in this study for both men and women. The 
incidence of thyroid carcinoma was higher for women 
than for men, with a higher relative risk in the female 
subgroup. Incidence of malignancy was highest in the 
50-60-year-old group. Given that studies show better 
survival for women and for younger patients, even when 
they present with advanced disease, as compared with 
older, male patients, prognosis should be considered a 
relevant factor in the treatment decision. Further 
research is needed to better understand the prognostic 
significance of age and gender. 
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